Literature DB >> 23526571

Discovery of a Series of Thiazole Derivatives as Novel Inhibitors of Metastatic Cancer Cell Migration and Invasion.

Shilong Zheng1, Qiu Zhong, Quan Jiang, Madhusoodanan Mottamal, Qiang Zhang, Naijue Zhu, Matthew E Burow, Rebecca A Worthylake, Guangdi Wang.   

Abstract

Effective inhibitors of cancer cell migration and invasion can potentially lead to clinical applications as therapy to block tumor metastasis, the primary cause of death in cancer patients. To this end we have designed and synthesized a series of thiazole derivatives that showed potent efficacy against cell migration and invasion in metastatic cancer cells. The most effective compound, 5k, was found to have an IC50 value of 176 nM in the dose-dependent transwell migration assays in MDA-MB-231cells. At the dose of 10 μM, 5k also blocked about 80% of migration in HeLa and A549 cells and 60% of invasion of MDA-MB-231 cells. Importantly, the majority of the derivatives exhibited no apparent cytotoxicity in the clonogenic assays. The low to negligible inhibition of cell proliferation is a desirable property of these anti-migration derivatives because they hold promise of low toxicity to healthy cells as potential therapeutic agents. Mechanistic studies analyzing the actin cytoskeleton by microscopy demonstrate that compound 5k substantially reduced cellular f-actin, and prevented localization of fascin to actin-rich membrane protrusions. These results suggest that the anti-migration activity may result from impaired actin structures in protrusions that are necessary to drive migration.

Entities:  

Keywords:  Thiazole derivatives; anti-invasion; anti-migration; f-actin; fascin; synthesis

Year:  2013        PMID: 23526571      PMCID: PMC3601768          DOI: 10.1021/ml300322n

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN: 1948-5875            Impact factor:   4.345


  33 in total

1.  Silibinin inhibits established prostate tumor growth, progression, invasion, and metastasis and suppresses tumor angiogenesis and epithelial-mesenchymal transition in transgenic adenocarcinoma of the mouse prostate model mice.

Authors:  Rana P Singh; Komal Raina; Girish Sharma; Rajesh Agarwal
Journal:  Clin Cancer Res       Date:  2008-12-01       Impact factor: 12.531

Review 2.  Antivascular actions of microtubule-binding drugs.

Authors:  Edward L Schwartz
Journal:  Clin Cancer Res       Date:  2009-04-07       Impact factor: 12.531

Review 3.  Role of MMPs in metastatic dissemination: implications for therapeutic advances.

Authors:  D Raffo; O Pontiggia; M Simian
Journal:  Curr Pharm Biotechnol       Date:  2011-11       Impact factor: 2.837

Review 4.  An updated patent therapeutic agents targeting MMPs.

Authors:  Zheng-gao Shi; Jin-pei Li; Lei-lei Shi; Xun Li
Journal:  Recent Pat Anticancer Drug Discov       Date:  2012-01       Impact factor: 4.169

Review 5.  PI3Kδ and PI3Kγ as targets for autoimmune and inflammatory diseases.

Authors:  Timothy D Cushing; Daniela P Metz; Douglas A Whittington; Lawrence R McGee
Journal:  J Med Chem       Date:  2012-09-13       Impact factor: 7.446

Review 6.  Matrix metalloproteinases in tumorigenesis: an evolving paradigm.

Authors:  Hui Hua; Minjing Li; Ting Luo; Yancun Yin; Yangfu Jiang
Journal:  Cell Mol Life Sci       Date:  2011-07-10       Impact factor: 9.261

Review 7.  Biological potential and structure-activity relationships of most recently developed vascular disrupting agents: an overview of new derivatives of natural combretastatin a-4.

Authors:  M Marrelli; F Conforti; G A Statti; X Cachet; S Michel; F Tillequin; F Menichini
Journal:  Curr Med Chem       Date:  2011       Impact factor: 4.530

Review 8.  Strategies for MMP inhibition in cancer: innovations for the post-trial era.

Authors:  Christopher Mark Overall; Carlos López-Otín
Journal:  Nat Rev Cancer       Date:  2002-09       Impact factor: 60.716

Review 9.  Dissemination and growth of cancer cells in metastatic sites.

Authors:  Ann F Chambers; Alan C Groom; Ian C MacDonald
Journal:  Nat Rev Cancer       Date:  2002-08       Impact factor: 60.716

10.  Discovery and optimization of a series of 2-aryl-4-amino-5-(3',4',5'-trimethoxybenzoyl)thiazoles as novel anticancer agents.

Authors:  Romeo Romagnoli; Pier Giovanni Baraldi; Maria Kimatrai Salvador; Delia Preti; Mojgan Aghazadeh Tabrizi; Andrea Brancale; Xian-Hua Fu; Jun Li; Su-Zhan Zhang; Ernest Hamel; Roberta Bortolozzi; Elena Porcù; Giuseppe Basso; Giampietro Viola
Journal:  J Med Chem       Date:  2012-05-21       Impact factor: 7.446

View more
  5 in total

1.  Design, synthesis, and biological evaluation of aminothiazole derivatives against the fungal pathogens Histoplasma capsulatum and Cryptococcus neoformans.

Authors:  Ahmed Khalil; Jessica A Edwards; Chad A Rappleye; Werner Tjarks
Journal:  Bioorg Med Chem       Date:  2014-12-10       Impact factor: 3.641

2.  Design, synthesis, and evaluation of novel heteroaromatic analogs of curcumin as anti-cancer agents.

Authors:  Nawras Samaan; Qiu Zhong; Jayjoel Fernandez; Guanglin Chen; Ali M Hussain; Shilong Zheng; Guangdi Wang; Qiao-Hong Chen
Journal:  Eur J Med Chem       Date:  2014-01-29       Impact factor: 6.514

Review 3.  Histone deacetylase inhibitors in clinical studies as templates for new anticancer agents.

Authors:  Madhusoodanan Mottamal; Shilong Zheng; Tien L Huang; Guangdi Wang
Journal:  Molecules       Date:  2015-03-02       Impact factor: 4.411

Review 4.  Advances in the proteomic discovery of novel therapeutic targets in cancer.

Authors:  Shanchun Guo; Jin Zou; Guangdi Wang
Journal:  Drug Des Devel Ther       Date:  2013-10-24       Impact factor: 4.162

5.  Modification and biological evaluation of thiazole derivatives as novel inhibitors of metastatic cancer cell migration and invasion.

Authors:  Shilong Zheng; Qiu Zhong; Yulan Xi; Madhusoodanan Mottamal; Qiang Zhang; Richard L Schroeder; Jayalakshmi Sridhar; Ling He; Harris McFerrin; Guangdi Wang
Journal:  J Med Chem       Date:  2014-07-18       Impact factor: 7.446

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.